在心力衰竭中,心脏器官的微血管功能障碍与保存的喷射分数:PROSE-HFpEF病例控制研究
Jerremy Weerts1, Blanche L M Schroen2, Arantxa Barandiarán Aizpurua2
1Department of Cardiology, CARIM Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre (MUMC+), PO Box 616, 6200 MD, Maastricht, The Netherlands. jerremy.weerts@mumc.nl.
Cardiovascular diabetology
|July 31, 2025
概括
系统性微血管功能障碍 (MVD) 与心脏衰竭有关,心脏衰竭具有保存的喷射分数 (HFpEF). HFpEF患者在多个血管床,特别是眼睛和脏中表现出MVD,这表明有潜在的性别特异性因素的系统性过程.
科学领域:
- 心脏病学 心脏病学
- 血管生物学 血管生物学
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 系统性微血管功能障碍 (MVD) 是心力衰竭的关键因素之一,心力衰竭的关键因素是心力衰竭与保存的射出分数 (HFpEF).
- 这项研究调查和比较了HFpEF患者和对照者的各种血管床的MVD.
研究的目的:
- 为了比较HFpEF患者的微血管功能与视网膜,皮肤和脏血管床的对照.
- 探索HFpEF内的微血管功能障碍中潜在的性别和糖尿病相互作用.
主要方法:
- 一项前性病例对照研究,涉及138名HFpEF患者 (≥60岁) 和2140名对照.
- 微血管评估包括视网膜血管口径 (CRVE/CRAE),视网膜扩张,皮肤微血管流动,皮肤高血,以及尿与肌素比率 (UACR).
- 对混因素 (年龄,性别,BMI,糖尿病等) 的分析进行了调整. 并测试了与性和糖尿病的相互作用.
主要成果:
- 对混调整的分析显示了视网膜血管口径 (CRVE,CRAE趋势) 和HFpEF患者更高的UACR的显著差异.
- 在调整后,皮肤微血管功能 (流动,高血压) 在组之间没有显著差异.
- 发现了性别差异:女性HFpEF患者的CRVE更窄,男性HFpEF患者的UACR更高. 在患有同时出现糖尿病的患者中观察到皮肤下部内皮质流动.
结论:
- 与对照组相比,HFpEF患者在多个血管床上表现出微血管差异.
- 调整后的分析证实了视网膜和脏微血管结构的持续差异,支持HFpEF中的全身MVD.
- 研究结果表明,HFpEF中存在系统性MVD过程,可能具有性别特异的病理生理机制.
相关概念视频
01:17Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
01:29Heart Failure II: Pathophysiology
44
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
44
01:27Heart Failure I: Introduction
55
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
55
01:26Heart Failure III: Clinical Manifestations
48
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
48
01:22Heart Failure Drugs: Diuretics
495
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
495
01:30Heart Failure V: Medical Management
25
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
25